Urinary incontinence in a Finnish population aged 70 and over. Prevalence of types, associated factors and self-reported treatments.

The investigation and treatment of female pelvic floor dysfunction. Dtsch Arztebl Int (2015) 3.12

Male urinary incontinence: prevalence, risk factors, and preventive interventions. Rev Urol (2009) 0.99

Predictors of institutionalization in elderly people living at home: the impact of incontinence and commode use in rural Japan. J Cross Cult Gerontol (2007) 0.84

Bacteriuria is associated with urge urinary incontinence in older women. Scand J Prim Health Care (2008) 0.80

The Prevalence, Subtypes and Obstetric Risk Factors of Urinary Incontinence in Reproductive Age Women Referred to Community Health Care Centers of Dezful, Iran- 2015. Int J Community Based Nurs Midwifery (2017) 0.75

Screening and prostate-cancer mortality in a randomized European study. N Engl J Med (2009) 35.94

Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91

MicroRNA expression profiling in prostate cancer. Cancer Res (2007) 8.04

Quality-of-life effects of prostate-specific antigen screening. N Engl J Med (2012) 7.21

Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67

Identification of 23 new prostate cancer susceptibility loci using the iCOGS custom genotyping array. Nat Genet (2013) 5.58

Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol (2010) 3.95

Nocturia frequency, bother, and quality of life: how often is too often? A population-based study in Finland. Eur Urol (2009) 3.92

Prostate cancer mortality reduction by prostate-specific antigen-based screening adjusted for nonattendance and contamination in the European Randomised Study of Screening for Prostate Cancer (ERSPC). Eur Urol (2009) 3.42

Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nat Genet (2011) 3.07

Intermittent androgen-deprivation therapy in prostate cancer: a critical review focused on phase 3 trials. Eur Urol (2013) 2.84

Effects of denosumab on bone mineral density in men receiving androgen deprivation therapy for prostate cancer. J Urol (2009) 2.83

Balancing the harms and benefits of early detection of prostate cancer. Cancer (2010) 2.71

2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncol (2013) 2.70

Tamoxifen as prophylaxis for prevention of gynaecomastia and breast pain associated with bicalutamide 150 mg monotherapy in patients with prostate cancer: a randomised, placebo-controlled, dose-response study. Eur Urol (2007) 2.41

Histological inflammation and risk of subsequent prostate cancer among men with initially elevated serum prostate-specific antigen (PSA) concentration in the Finnish prostate cancer screening trial. BJU Int (2013) 2.35

TMPRSS2:ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res (2008) 2.16

The effect of study arm on prostate cancer treatment in the large screening trial ERSPC. Int J Cancer (2010) 2.15

Reproductive factors associated with nocturia and urinary urgency in women: a population-based study in Finland. Am J Obstet Gynecol (2008) 2.10

Cholesterol-lowering drugs and prostate cancer risk: a population-based case-control study. Cancer Epidemiol Biomarkers Prev (2007) 2.05

Bicalutamide as immediate therapy either alone or as adjuvant to standard care of patients with localized or locally advanced prostate cancer: first analysis of the early prostate cancer program. J Urol (2002) 2.02

Mitochondrial DNA polymorphisms associated with longevity in a Finnish population. Hum Genet (2002) 2.00

No excess mortality after prostate biopsy: results from the European Randomized Study of Screening for Prostate Cancer. BJU Int (2010) 1.94

The role of genetic markers in the management of prostate cancer. Eur Urol (2012) 1.88

Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet (2002) 1.86

Efficacy and safety of long-term treatment with the dual 5 alpha-reductase inhibitor dutasteride in men with symptomatic benign prostatic hyperplasia. Eur Urol (2004) 1.79

Prevalence of symptoms related to interstitial cystitis in women: a population based study in Finland. J Urol (2002) 1.77

Acceptability and complications of prostate biopsy in population-based PSA screening versus routine clinical practice: a prospective, controlled study. Urology (2002) 1.74

The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study. Eur Urol (2011) 1.73

The effect of dutasteride on the usefulness of prostate specific antigen for the diagnosis of high grade and clinically relevant prostate cancer in men with a previous negative biopsy: results from the REDUCE study. J Urol (2010) 1.73

Pooled genome linkage scan of aggressive prostate cancer: results from the International Consortium for Prostate Cancer Genetics. Hum Genet (2006) 1.70

Cyclosporine A and pentosan polysulfate sodium for the treatment of interstitial cystitis: a randomized comparative study. J Urol (2005) 1.69

The FinnProstate Study VII: intermittent versus continuous androgen deprivation in patients with advanced prostate cancer. J Urol (2012) 1.67

Is nocturia equally common among men and women? A population based study in Finland. J Urol (2006) 1.64

Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects. Eur Urol (2012) 1.57

Predictors of institutionalization in an older population during a 13-year period: the effect of urge incontinence. J Gerontol A Biol Sci Med Sci (2003) 1.57

Effects of simvastatin, acetylsalicylic acid, and rosiglitazone on proliferation of normal and cancerous prostate epithelial cells at therapeutic concentrations. Prostate (2009) 1.56

The effect of baseline testosterone on the efficacy of degarelix and leuprolide: further insights from a 12-month, comparative, phase III study in prostate cancer patients. Urology (2012) 1.53

Smoking and bladder symptoms in women. Obstet Gynecol (2011) 1.52

A meta-analysis of genome-wide association studies to identify prostate cancer susceptibility loci associated with aggressive and non-aggressive disease. Hum Mol Genet (2012) 1.47

Transurethral needle ablation for the treatment of chronic pelvic pain syndrome (category III prostatitis): a randomized, sham-controlled study. Urology (2002) 1.46

Health-related quality of life in the Finnish trial of screening for prostate cancer. Eur Urol (2012) 1.46

Impact of LUTS using bother index in DAN-PSS-1 questionnaire. Eur Urol (2006) 1.44

Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst (2004) 1.44

Urine flow curve shapes in adults with earlier vesicoureteral reflux. Eur Urol (2007) 1.42

Male fetal sex is associated with earlier onset of placental abruption. Acta Obstet Gynecol Scand (2010) 1.42

miR-193b is an epigenetically regulated putative tumor suppressor in prostate cancer. Int J Cancer (2010) 1.42

Prostate cancer and PSA among statin users in the Finnish prostate cancer screening trial. Int J Cancer (2010) 1.41

Antidiabetic medication and prostate cancer risk: a population-based case-control study. Am J Epidemiol (2008) 1.41

Blood loss and postoperative complications associated with transurethral resection of the prostate after pretreatment with dutasteride. BJU Int (2007) 1.37

Bicalutamide (150 mg) versus placebo as immediate therapy alone or as adjuvant to therapy with curative intent for early nonmetastatic prostate cancer: 5.3-year median followup from the Scandinavian Prostate Cancer Group Study Number 6. J Urol (2004) 1.35

Association of SPINK1 expression and TMPRSS2:ERG fusion with prognosis in endocrine-treated prostate cancer. Clin Cancer Res (2010) 1.33

EZH2, Ki-67 and MCM7 are prognostic markers in prostatectomy treated patients. Int J Cancer (2008) 1.31

The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer (2006) 1.30

Differences between local and review urinary cytology in diagnosis of bladder cancer. An interobserver multicenter analysis. Eur Urol (2002) 1.30

A systematic evaluation of factors associated with nocturia--the population-based FINNO study. Am J Epidemiol (2009) 1.29

Global self-rated health data from a longitudinal study predicted mortality better than comparative self-rated health in old age. J Clin Epidemiol (2005) 1.28

Finnish multicenter study comparing intermittent to continuous androgen deprivation for advanced prostate cancer: interim analysis of prognostic markers affecting initial response to androgen deprivation. J Urol (2008) 1.22

Compelling evidence for a prostate cancer gene at 22q12.3 by the International Consortium for Prostate Cancer Genetics. Hum Mol Genet (2007) 1.20

Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res (2004) 1.17

Loss of PTEN is associated with aggressive behavior in ERG-positive prostate cancer. Cancer Epidemiol Biomarkers Prev (2013) 1.17

Depressive symptoms increase the incidence of nocturia: Tampere Aging Male Urologic Study (TAMUS). J Urol (2008) 1.16

Effect of lower urinary tract symptoms on the incidence of erectile dysfunction. J Urol (2005) 1.16

Characterization of breast cancer types by texture analysis of magnetic resonance images. Acad Radiol (2009) 1.15

Cross-national determinants of quality of life from six longitudinal studies on aging: the CLESA project. Aging Clin Exp Res (2003) 1.14

Inflammatory markers and physical performance among nonagenarians. J Gerontol A Biol Sci Med Sci (2010) 1.14

Self-rated health and mortality in older men and women: a time-dependent covariate analysis. Arch Gerontol Geriatr (2007) 1.13

RAD21 and KIAA0196 at 8q24 are amplified and overexpressed in prostate cancer. Genes Chromosomes Cancer (2004) 1.13

Genetic alterations and changes in expression of histone demethylases in prostate cancer. Prostate (2010) 1.12

Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. Int J Cancer (2005) 1.11

Expression and gene copy number analysis of ERBB2 oncogene in prostate cancer. Am J Pathol (2002) 1.11

Genome-wide linkage scan for prostate cancer susceptibility in Finland: evidence for a novel locus on 2q37.3 and confirmation of signal on 17q21-q22. Int J Cancer (2011) 1.09

Long-term follow-up study of radioiodine treatment of hyperthyroidism. Clin Endocrinol (Oxf) (2004) 1.09

Apolipoprotein E genotype is related to plasma levels of C-reactive protein and lipids and to longevity in nonagenarians. Clin Endocrinol (Oxf) (2006) 1.08

Prophylactic breast irradiation with a single dose of electron beam radiotherapy (10 Gy) significantly reduces the incidence of bicalutamide-induced gynecomastia. Int J Radiat Oncol Biol Phys (2004) 1.08

Surgically staged high-risk endometrial cancer: randomized study of adjuvant radiotherapy alone vs. sequential chemo-radiotherapy. Gynecol Oncol (2008) 1.06

Body mass index, waist circumference, and waist-to-hip ratio as predictors of mortality in nonagenarians: the Vitality 90+ Study. J Gerontol A Biol Sci Med Sci (2011) 1.05

Nocturia and obesity: a population-based study in Finland. Am J Epidemiol (2006) 1.05

Use of aspirin, but not other non-steroidal anti-inflammatory drugs is associated with decreased prostate cancer risk at the population level. Eur J Cancer (2012) 1.05

Onset of loneliness in older adults: results of a 28 year prospective study. Eur J Ageing (2011) 1.04

Bidirectional relationship between depression and erectile dysfunction. J Urol (2007) 1.04

HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev (2013) 1.03

Sarcopenia during androgen-deprivation therapy for prostate cancer. J Clin Oncol (2012) 1.03

False-positive screening results in the European randomized study of screening for prostate cancer. Eur J Cancer (2011) 1.02

MRI texture analysis in multiple sclerosis: toward a clinical analysis protocol. Acad Radiol (2010) 1.01

Estimation of prostate cancer risk on the basis of total and free prostate-specific antigen, prostate volume and digital rectal examination. Eur Urol (2002) 1.01

Characterization of the role of distinct plasma cell-free DNA species in age-associated inflammation and frailty. Aging Cell (2013) 1.01

Germ-line alterations in MSR1 gene and prostate cancer risk. Clin Cancer Res (2003) 1.00

Prevalence of clinically confirmed interstitial cystitis in women: a population based study in Finland. J Urol (2005) 0.99

Medical history, cognitive status and mobility at the age of 90. A population-based study in Tampere, Finland. Aging Clin Exp Res (2003) 0.99

Negative bacterial polymerase chain reaction (PCR) findings in prostate tissue from patients with symptoms of chronic pelvic pain syndrome (CPPS) and localized prostate cancer. Prostate (2003) 0.98

Non-Hodgkin lymphoma response evaluation with MRI texture classification. J Exp Clin Cancer Res (2009) 0.98

Telephone intervention and quality of life in patients with breast cancer. Cancer Nurs (2009) 0.97

Unemployment, depressiveness and disability retirement: a follow-up study of the Finnish HeSSup population sample. Soc Psychiatry Psychiatr Epidemiol (2009) 0.96

Predictors of mortality in men and women aged 90 and older: a nine-year follow-up study in the Vitality 90+ study. Age Ageing (2013) 0.96